2012
HIV: Cell Binding and Entry
Wilen CB, Tilton JC, Doms RW. HIV: Cell Binding and Entry. Cold Spring Harbor Perspectives In Medicine 2012, 2: a006866. PMID: 22908191, PMCID: PMC3405824, DOI: 10.1101/cshperspect.a006866.Peer-Reviewed Original ResearchConceptsHIV entryViral tropismPrimary cellular receptor CD4Human immunodeficiency virus (HIV) replicationAbility of HIVImmunodeficiency virus replicationHost immune responseHuman immune systemCellular receptor CD4Immune responseCellular coreceptorTherapeutic interventionsImmune systemReceptor CD4Virus replicationHIVCell bindingHost cell cytoplasmTropismHost cell membraneTrigger fusionCell cytoplasmCD4Major rolePathogenesis
2011
Molecular Mechanisms of HIV Entry
Wilen CB, Tilton JC, Doms RW. Molecular Mechanisms of HIV Entry. Advances In Experimental Medicine And Biology 2011, 726: 223-242. PMID: 22297516, DOI: 10.1007/978-1-4614-0980-9_10.Peer-Reviewed Original ResearchConceptsHIV entryOnly viral surface proteinHuman immunodeficiency virus (HIV) entryHumoral immune responseMembrane fusion machineryCoreceptor-binding siteHost protein CD4Viral surface proteinsHIV infectionSmall molecule inhibitorsImmune responseChemokine coreceptorsFusion machineryViral tropismClinical treatmentVirus entryMolecular mechanismsHost cellsFacilitates exposureMolecule inhibitorsGp41 subunitSurface proteinsViral genomeAmino acidsCD4
2010
A Maraviroc-Resistant HIV-1 with Narrow Cross-Resistance to Other CCR5 Antagonists Depends on both N-Terminal and Extracellular Loop Domains of Drug-Bound CCR5
Tilton JC, Wilen CB, Didigu CA, Sinha R, Harrison JE, Agrawal-Gamse C, Henning EA, Bushman FD, Martin JN, Deeks SG, Doms RW. A Maraviroc-Resistant HIV-1 with Narrow Cross-Resistance to Other CCR5 Antagonists Depends on both N-Terminal and Extracellular Loop Domains of Drug-Bound CCR5. Journal Of Virology 2010, 84: 10863-10876. PMID: 20702642, PMCID: PMC2950574, DOI: 10.1128/jvi.01109-10.Peer-Reviewed Original ResearchMeSH KeywordsBase SequenceBinding SitesCCR5 Receptor AntagonistsCell LineCohort StudiesCyclohexanesDNA PrimersDrug Resistance, ViralHIV Envelope Protein gp120HIV Fusion InhibitorsHIV InfectionsHIV-1HumansIn Vitro TechniquesMaravirocModels, BiologicalMutant ProteinsMutationPeptide FragmentsProtein Structure, TertiaryReceptors, CCR5TriazolesConceptsCCR5 antagonistsLow CCR5 levelsTreatment-experienced patientsPlasma viral RNACCR5 antagonist maravirocCourse of treatmentHigh-level resistanceMVC resistanceMVC treatmentVirologic failureExtracellular loopCCR5 levelsTreatment regimensCross-resistance profilesCXCR4 useV3 loopCCR5 useHIV entryHIV-1Viral envelope proteinsCCR5V4 loopsAntagonistMaravirocPatients